ArticleCancer research2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 124 citations in OpenAlex.
- CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.Frontiers in immunology · 2021Trial
- Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition.Viruses · 2026Review
- CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy.International journal of molecular sciences · 2026Article
- CCL5 improves radiation resistance through activation of the AMPK/mTOR pathway in adenoid cystic carcinoma.Journal of translational medicine · 2026Article
- Quantitative phosphoproteomic profiling of CCL5/CCR5 signaling cascade in melanoma cells.Frontiers in oncology · 2026Article
- Chimeric diphtheria toxin-CCL8 cytotoxic peptide for breast cancer management.Molecular oncology · 2025Article
- Targeting the CCL5/CCR5 axis in tumor-stromal crosstalk to overcome cisplatin resistance in neuroendocrine prostate cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Promotion of the invasion and metastasis of breast cancer by B7-H3 through CCR5High tumor-associated macrophages.Cancer cell international · 2025Article
- CCR5 + T cells as a potential biomarker for primary Sjögren's disease based on bioinformatics analysis.Clinical rheumatology · 2025Article
- Gene Expression Changes as Biomarkers of Immunosenescence in Bulgarian Individuals of Active Age.Biomedicines · 2025Article
- Multiparameter diagnostic model using S100A9, CCL5 and blood biomarkers for nasopharyngeal carcinoma.Scientific reports · 2025Article
- Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.Biological research · 2025Article
- Blockade of CCR5Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- [Research Progresses on the Effects of CCL4 on Immune Escape in Tumor Microenvironment].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- SOSTDC1 Nuclear Translocation Facilitates BTIC Maintenance and CHD1-Mediated HR Repair to Promote Tumor Progression and Olaparib Resistance in TNBC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Targeting cytokine and chemokine signaling pathways for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Article
- Immune Cell Migration to Cancer.Cells · 2024Review
- Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 1 institution in 1 country.
Xuanmao JiaoPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Doylestown, Pennsylvania.
Marco A Velasco-VelázquezDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Min WangPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Doylestown, Pennsylvania.
Zhiping LiDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Hallgeir RuiDepartment of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Amy R PeckDepartment of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin.
James E KorkolaOHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Xuelian ChenDivision of Biomedical Sciences, and Periodontology, Diagnostic Sciences & Dental Hygiene, School of Dentistry, University of Southern California, Los Angeles, California.
Shaohua XuDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
James B DuHadawayLankenau Institute for Medical Research, Wynnewood, Pennsylvania.
Sandra Guerrero-RodriguezGraduate Program in Biochemical Sciences, National Autonomous University of Mexico, Mexico City, Mexico.
Sankar AddyaDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Daniela SicoliDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Zhaomei MuRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
Gang ZhangDivision of Biomedical Sciences, and Periodontology, Diagnostic Sciences & Dental Hygiene, School of Dentistry, University of Southern California, Los Angeles, California.
Andres StuckyDivision of Biomedical Sciences, and Periodontology, Diagnostic Sciences & Dental Hygiene, School of Dentistry, University of Southern California, Los Angeles, California.
Xi ZhangDivision of Biomedical Sciences, and Periodontology, Diagnostic Sciences & Dental Hygiene, School of Dentistry, University of Southern California, Los Angeles, California.
Massimo CristofanilliRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
Alessandro FatatisDepartment of Pharmacology & Physiology, Drexel University, Philadelphia, Pennsylvania.
Joe W GrayOHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Jiang F ZhongDivision of Biomedical Sciences, and Periodontology, Diagnostic Sciences & Dental Hygiene, School of Dentistry, University of Southern California, Los Angeles, California.
George C PrendergastLankenau Institute for Medical Research, Wynnewood, Pennsylvania.
Richard G PestellPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Doylestown, Pennsylvania. richard.pestell@gmail.com.
Nanyang Technological University · SG
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Claudio Guillermo Giraudo · 1995 to 2026
$94.8MInitiation and Maintenance In Mammary TumorigenesisR01CA075503 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 1998 to 2011
$4.6MCYCLIN D1 FUNCTION IN PROSTATE CANCERR01CA086072 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2001 to 2013
$3.3MREGULATION OF CYCLIN D1 EXPRESSIONR01CA070896 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2000 to 2010
$3.2MMulti-phase Microfluidic Devices for Characterization of Circulating Tumor CellsR01CA164509 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHONG, JOHN · 2012 to 2016
$2.0MMolecular Characteristics of Treatment-resistant High-risk NeuroblastomaR01CA197903 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHONG, JOHN · 2016 to 2020
$1.9MProlactin pathways and metastatic progression of ER-positive breast cancerR01CA188575 · NCI · THOMAS JEFFERSON UNIVERSITY · PI RUI, HALLGEIR · 2015 to 2019
$1.8MNCI NIH HHS P30 CA056036NCI NIH HHS R01 CA070896NCI NIH HHS R01 CA075503NCI NIH HHS R01 CA086072NCI NIH HHS R01 CA164509NCI NIH HHS R01 CA188575NCI NIH HHS R01 CA197903
Abstract
The functional significance of the chemokine receptor CCR5 in human breast cancer epithelial cells is poorly understood. Here, we report that CCR5 expression in human breast cancer correlates with poor outcome. CCR5
Indexed as
AnimalsAntineoplastic AgentsBreast NeoplasmsCCR5 Receptor AntagonistsCell Line, TumorCell ProliferationCell Transformation, NeoplasticDNA DamageDNA RepairEpithelial CellsFemaleGene Expression Regulation, NeoplasticHumansMaravirocMiceMice, NudeAntineoplastic AgentsCCR5 protein, humanCCR5 Receptor AntagonistsMaravirocPhosphatidylinositol 3-KinasesPiperazinesPyrimidinesReceptors, CCR5vicriviroc
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.